top of page
Buscar

Thermosome grants Avenor global licence to heat-activated oncology platform and Phase II-ready THE001

Foto del escritor: nuaxia
nuaxia
hace 3 horas
1 min de lectura

Thermosome has granted Avenor Therapeutics exclusive worldwide rights to its heat-activated oncology drug-delivery platform and Phase II-ready THE001 candidate, supporting a combined drug and hyperthermia development strategy.


Thermosome announced on 17 November 2026 that it had entered into an exclusive global licensing agreement with Avenor Therapeutics covering its thermosensitive liposome platform, seven patent families and investigational Phase II-ready THE001 programme, which combines heat-triggered doxorubicin delivery with regional hyperthermia for initial development in soft tissue sarcoma.


Avenor has also secured separate North American rights to a CE-marked hyperthermia system from Medlogix, supporting an integrated drug-device approach; financial terms of the Thermosome agreement were not disclosed, and THE001 remains investigational despite existing orphan-drug designations.

Field

Content

Licensor

Thermosome

Licensee

Avenor Therapeutics

Announcement Date

17 November 2026

Agreement Type

Exclusive global licensing agreement

Territorial Scope

Worldwide

Licensed Platform

Thermosensitive liposome drug-delivery technology

Licensed Intellectual Property

Seven patent families

Lead Candidate

THE001

Development Stage

Phase II-ready

Therapeutic Area

Oncology

Initial Indication

Soft tissue sarcoma

Drug-Delivery Mechanism

Heat-triggered doxorubicin release using regional hyperthermia

Additional Technology Partner

Medlogix

Separate Device Rights

North American rights to a CE-marked hyperthermia system

Financial Terms

Not disclosed

Regulatory Status

THE001 remains investigational; existing orphan-drug designations do not constitute marketing approval

Primary Source

https://www.globenewswire.com/news-release/2026/11/17/3404509/0/en/thermosome-closes-exclusive-global-licensing-agreement-with-avenor-therapeutics.html


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentarios

Obtuvo 0 de 5 estrellas.
Aún no hay calificaciones

Agrega una calificación
bottom of page